{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:58:48Z","timestamp":1794268728922,"version":"4.9.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Janus kinase inhibitors [JAKi] are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors, and are increasingly being used in the treatment of immune-mediated diseases. Tofacitinib, a non-selective JAKi, is now approved for moderate-to-severe ulcerative colitis [UC] that is refractory or intolerant to tumour necrosis factor inhibitors [TNFi]. Whereas tofacitinib is associated with the advantages of oral administration, rapid onset of action, and lack of immunogenicity over TNFi, there are many safety considerations to take into account such as the risk of thromboembolism, infections, and hyperlipidaemia: each with specific nuances pertaining to prevention and monitoring strategies. Considerations such as pregnancy, breastfeeding, and history of malignancy also are to be navigated with utmost caution, given that very few data are available for guidance. With the use of JAKi in the real world progressively over time, safety implications will become more lucid, including caveats pertaining to JAK selectivity and gut-selective JAKi, as well as mechanistic data pertaining to adverse effects. This Viewpoint serves as a practical guide for clinicians managing inflammatory bowel disease [IBD] patients to navigate safety concerns around JAKi, including preventive and monitoring strategies.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaa017","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T20:10:37Z","timestamp":1580415037000},"page":"S755-S760","source":"Crossref","is-referenced-by-count":70,"title":["JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4729-1485","authenticated-orcid":false,"given":"Manasi","family":"Agrawal","sequence":"first","affiliation":[{"name":"Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York NY, USA"},{"name":"Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[{"name":"Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,1]]},"reference":[{"key":"2020080105370554200_CIT0001","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"2020080105370554200_CIT0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2020080105370554200_CIT0003","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2020080105370554200_CIT0004","year":"2019"},{"key":"2020080105370554200_CIT0005","year":"2019"},{"key":"2020080105370554200_CIT0006","volume-title":"Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn\u2019s Disease [Diversity1]","year":"2019"},{"key":"2020080105370554200_CIT0007"},{"key":"2020080105370554200_CIT0008","volume-title":"Efficacy ans Safety of TD-1473 in Ulcerative Colitis [RHEA]. 2019"},{"key":"2020080105370554200_CIT0009","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020080105370554200_CIT0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2020080105370554200_CIT0011","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020080105370554200_CIT0012","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"2020080105370554200_CIT0013","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/1756-185X.13516","article-title":"Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data","volume":"22","author":"Lee","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2020080105370554200_CIT0014","first-page":"799","article-title":"Genome-wide trans-ancestry metaanalysis of herpes zoster in RA and Pso patients treated with tofacitinib","volume":"67","author":"Bing","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020080105370554200_CIT0015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib [the FITZROY study]: results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2020080105370554200_CIT0016","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 [Upadacitinib], an oral JAK1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from Celest","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"2020080105370554200_CIT0017","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020080105370554200_CIT0018","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020080105370554200_CIT0019","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2020080105370554200_CIT0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2020080105370554200_CIT0021","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020080105370554200_CIT0022","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020080105370554200_CIT0023","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020080105370554200_CIT0024","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2020080105370554200_CIT0025","volume-title":"XELJANZ [tofacitinib]: Increased risk of pulmonary embolism and mortality in rheumatoid arthritis patients receiving 10mg twice daily in a clinical trial","author":"Pfizer","year":"2019"},{"key":"2020080105370554200_CIT0026","volume-title":"Xeljanz approval History","year":"2019"},{"key":"2020080105370554200_CIT0027","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","author":"Xie","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020080105370554200_CIT0028","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020080105370554200_CIT0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK Inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"2020080105370554200_CIT0030","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"2020080105370554200_CIT0031","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2020080105370554200_CIT0032","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020080105370554200_CIT0033","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020080105370554200_CIT0034","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2020080105370554200_CIT0035","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020080105370554200_CIT0036","author":"Pfizer Inc","year":"2019"},{"key":"2020080105370554200_CIT0037","first-page":"533","article-title":"Janus kinase JAK1 maintains the ovarian reserve of primordial follicles in the mouse ovary","volume":"24","author":"Sutherland","year":"2018","journal-title":"Mol Hum Reprod"},{"key":"2020080105370554200_CIT0038","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"2020080105370554200_CIT0039","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"2020080105370554200_CIT0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","article-title":"Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis","volume":"47","author":"Maneiro","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2020080105370554200_CIT0041","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020080105370554200_CIT0042","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"key":"2020080105370554200_CIT0043","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"key":"2020080105370554200_CIT0044","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"2020080105370554200_CIT0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","article-title":"Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture?","volume":"36","author":"Coloma","year":"2013","journal-title":"Drug Saf"},{"key":"2020080105370554200_CIT0046","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMp0905338","article-title":"The new Sentinel Network \u2013 improving the evidence of medical-product safety","volume":"361","author":"Platt","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa017\/32307506\/jjaa017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/Supplement_2\/S755\/33556853\/jjaa017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/Supplement_2\/S755\/33556853\/jjaa017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:17:10Z","timestamp":1614212230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/Supplement_2\/S755\/5719575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":46,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2020,2,1]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa017","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,2,1]]}}}